Director Makes Bold Move with Major Stock Purchase in Integra Lifesciences

Tip Ranks
2025.11.07 02:07
portai
I'm PortAI, I can summarize articles.

Director Jeffrey Graves of Integra Lifesciences (IART) purchased 9,000 shares worth $102,150 on November 6, 2025. The company faces challenges, including a revenue miss in Q3, leading to mixed updates on stock price targets from various analysts. Truist lowered its target, while JPMorgan raised it, and Citi also reduced its target due to ongoing issues. Despite a 5% organic revenue growth, the company revised its full-year guidance downward. Overall, the sentiment on IART stock remains cautious, with a Neutral rating from TipRanks' AI Analyst.

New insider activity at Integra Lifesciences ( (IART) ) has taken place on November 6, 2025.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Director Jeffrey Graves has made a significant investment in Integra Lifesciences by purchasing 9,000 shares of the company’s stock, amounting to a total value of $102,150.

Recent Updates on IART stock

In the last 24 hours, Integra LifeSciences has experienced significant developments impacting its stock price targets. Truist lowered its price target due to a surprising Q3 revenue miss, despite previous outlook adjustments, overshadowing improvements in profitability and free cash flow. The revenue shortfall was attributed to intra-quarter issues and supply chain challenges. Meanwhile, JPMorgan raised its price target, updating the company’s model, while Citi reduced its target due to ongoing revenue shortfalls and a lowered outlook amid supply chain disruptions. Despite these challenges, Integra LifeSciences reported strong operational efficiency, a 5% organic revenue growth, and strategic advancements, including the early relaunch of key products, which were tempered by challenges in the ENT and Private Label segments. The company revised its full-year guidance downward, reflecting these mixed results.

Spark’s Take on IART Stock

According to Spark, TipRanks’ AI Analyst, IART is a Neutral.

Integra Lifesciences faces significant financial and operational challenges, reflected in its low financial performance and valuation scores. The technical analysis indicates bearish momentum, further weighing down the stock’s outlook. While the earnings call highlighted some strategic advancements, the overall sentiment remains cautious due to ongoing disruptions and lowered guidance.

To see Spark’s full report on IART stock, click here.

More about Integra Lifesciences

YTD Price Performance: -50.48%

Average Trading Volume: 1,212,983

Technical Sentiment Signal: Strong Sell

Current Market Cap: $880.2M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer